They had experienced symptoms of polycythemia vera for an average of 7 years.
他们平均已患有真性多血症的症状达7年之久。
Objective: To investigate the role of EPO in the pathogenesis of high altitude polycythemia (HAPC).
目的:探讨EPO在高原红细胞增多症发病机制中的作用。
Neonatal low birth weights, respiratory distress syndrome and polycythemia are risk factors for THP.
新生儿低出生体质量、呼吸窘迫综合征及红细胞增多症是THP的危险因素。
Objective To characterize clinical feature of rhinorrhagia correlated with high altitude polycythemia (HAPC).
目的探讨高原红细胞增多症(HAPC)患者鼻出血的临床特点。
Objective To investigate the growth of endogenous erythroid colony (EEC) in polycythemia vera (PV) patients and its clinical significance.
目的了解真性红细胞增多症(PV)患者内源性红系集落(EEC)生长情况及其临床意义。
Objective To study the mechanism, clinical manifestations and pathophysiological characteristics of erythromelalgia accompanying polycythemia vera.
目的研究伴发于真性红细胞增多症的红斑性肢痛症发病机制、临床表现、病理生理特点。
These results proved that polycythemia may play an important role in pathogenesis of chronic hypoxic pulmonary hypertension and cardiac hypertrophy.
以上结果表明红细胞增多可能在慢性缺氧性肺动脉高压和右室肥大发生起着重要作用。
The above results proved that polycythemia might play an important role in pathogenesis of hypoxic pulmonary hypertension and myocardial hypertrophy.
以上结果表明,红细胞增多在缺氧性肺动脉高压和右室肥大中起着重要作用。
Objective To investigate the alteration of serum thyroid hormone level in the patients with high altitude polycythemia (HAPC) and its clinical significance.
目的探讨高原红细胞增多症(HAPC)患者血清甲状腺激素的变化及其临床意义。
Because polycythemia may require dose reductions or discontinuation of therapy, hematocrit should be obtained at baseline, 3 to 6 months after initiation of therapy, and annually thereafter.
由于红细胞增多可能需要降低剂量或停止治疗,故应在开始治疗前、初始治疗后的3 ~6个月以及随后的每年检测红细胞比积。
Because polycythemia may require dose reductions or discontinuation of therapy, hematocrit should be obtained at baseline, 3 to 6 months after initiation of therapy, and annually thereafter.
由于红细胞增多可能需要降低剂量或停止治疗,故应在开始治疗前、初始治疗后的3 ~6个月以及随后的每年检测红细胞比积。
应用推荐